María Koehler

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko et al. · The Lancet Oncology · 2016 · 1.8K citations

Medicine, Oncology, Pharmacology +17

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

Nicholas C. Turner, Jungsil Ro, Fabrice André et al. · New England Journal of Medicine · 2015 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +10

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

Kimberly Blackwell, Harold J. Burstein, Anna Maria Storniolo et al. · Journal of Clinical Oncology · 2010 · 960 citations · Full text

Medicine, Oncology, Pharmacology +17

Plasma <i>ESR1</i> Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

Charlotte Fribbens, Ben O’Leary, Lucy Kilburn et al. · Journal of Clinical Oncology · 2016 · 718 citations

Medicine, Oncology, Pharmacology +17

Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

Angelo Di Leo, Henry Gómez, Zeba Aziz et al. · Journal of Clinical Oncology · 2008 · 421 citations · Full text

Medicine, Oncology, Pharmacology +17